Petter Bjornstad, MD

Executive Director
University of Washington School of Medicine, and Seattle Children's Hospital, United States

Presentation(s):

• The Role of SGLT2 Inhibitors and GLP-1R Agonists in Treatment and Prevention of DKD: the Adrian Spitzer Lectureship

  Saturday, April 26, 2025
  11:00am – 11:30am HST

  Disclosure(s): AstraZeneca (Ongoing) (Products/Services: Advisory Committee, Consultant, Research Support including clinical trials & the principal or named investigator); Boehringer-Ingelheim (Ongoing) (Products/Services: Advisory Committee, Consultant); Horizon / Amgen (Ongoing) (Products/Services: Consultant); Lilly (Ongoing) (Products/Services: Advisory Committee, Consultant); Merck (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Novo Nordisk (Ongoing) (Products/Services: Advisory Committee, Consultant, Research Support including clinical trials & the principal or named investigator)